ACOG - קצב צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים alphacognition.com

Alpha Cognition develops Alzheimer's treatments, demonstrating resilience to crises and an absence of seasonality. However, business success is limited by strict regulatory control and the risks of clinical trial failures. The annual sales growth rate over a 12-month period reflects the market consensus, where the current metric equals 171.60. Future capital will be impacted by the promotion costs of Zunveyl and the speed of its commercial adoption.

This indicator measures the rolling year cash flow dynamics, capturing the business scaling speed relative to the previous period to assess revenue sustainability. By analyzing the TTM revenue growth trajectory compared to the previous year, investors determine the market potential of Alpha Cognition (ACOG), where strong dynamics confirm the successful implementation of the Alzheimer's disease drug and protection against pricing pressure from generics.